LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer
Public ClinicalTrials.gov record NCT01015118. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Multicenter, Randomised, Double-blind Phase III Trial to Investigate the Efficacy and Safety of BIBF 1120 in Combination With Carboplatin and Paclitaxel Compared to Placebo Plus Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer
Study identification
- NCT ID
- NCT01015118
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 1,366 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- Paclitaxel Drug
- BIBF 1120 Drug
- Carboplatin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 16, 2009
- Primary completion
- Mar 31, 2013
- Completion
- Sep 14, 2016
- Last update posted
- Dec 6, 2017
2009 – 2016
United States locations
- U.S. sites
- 33
- U.S. states
- 21
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1199.15.10113 Boehringer Ingelheim Investigational Site | Tucson | Arizona | — | — |
| 1199.15.10030 Boehringer Ingelheim Investigational Site | Long Beach | California | — | — |
| 1199.15.10001 Boehringer Ingelheim Investigational Site | Santa Rosa | California | — | — |
| 1199.15.10005 Boehringer Ingelheim Investigational Site | Englewood | Colorado | — | — |
| 1199.15.10028 Boehringer Ingelheim Investigational Site | New Haven | Connecticut | — | — |
| 1199.15.10014 Boehringer Ingelheim Investigational Site | Orlando | Florida | — | — |
| 1199.15.10010 Boehringer Ingelheim Investigational Site | Augusta | Georgia | — | — |
| 1199.15.10004 Boehringer Ingelheim Investigational Site | Savannah | Georgia | — | — |
| 1199.15.10011 Boehringer Ingelheim Investigational Site | Louisville | Kentucky | — | — |
| 1199.15.10003 Boehringer Ingelheim Investigational Site | Marrero | Louisiana | — | — |
| 1199.15.10017 Boehringer Ingelheim Investigational Site | Detroit | Michigan | — | — |
| 1199.15.10103 Boehringer Ingelheim Investigational Site | Minneapolis | Minnesota | — | — |
| 1199.15.10002 Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| 1199.15.10012 Boehringer Ingelheim Investigational Site | Charlotte | North Carolina | — | — |
| 1199.15.10020 Boehringer Ingelheim Investigational Site | Winston-Salem | North Carolina | — | — |
| 1199.15.10019 Boehringer Ingelheim Investigational Site | Bismarck | North Dakota | — | — |
| 1199.15.10024 Boehringer Ingelheim Investigational Site | Canton | Ohio | — | — |
| 1199.15.10025 Boehringer Ingelheim Investigational Site | Cleveland | Ohio | — | — |
| 1199.15.10029 Boehringer Ingelheim Investigational Site | Cleveland | Ohio | — | — |
| 1199.15.10021 Boehringer Ingelheim Investigational Site | Portland | Oregon | — | — |
| 1199.15.10013 Boehringer Ingelheim Investigational Site | Abington | Pennsylvania | — | — |
| 1199.15.10016 Boehringer Ingelheim Investigational Site | Allentown | Pennsylvania | — | — |
| 1199.15.10008 Boehringer Ingelheim Investigational Site | Providence | Rhode Island | — | — |
| 1199.15.10102 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 1199.15.10006 Boehringer Ingelheim Investigational Site | Chattanooga | Tennessee | — | — |
| 1199.15.10104 Boehringer Ingelheim Investigational Site | Austin | Texas | — | — |
| 1199.15.10100 Boehringer Ingelheim Investigational Site | Bedford | Texas | — | — |
| 1199.15.10107 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 1199.15.10108 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 1199.15.10110 Boehringer Ingelheim Investigational Site | Fort Worth | Texas | — | — |
| 1199.15.10007 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1199.15.10105 Boehringer Ingelheim Investigational Site | Spokane | Washington | — | — |
| 1199.15.10112 Boehringer Ingelheim Investigational Site | Vancouver | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 248 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01015118, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 6, 2017 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01015118 live on ClinicalTrials.gov.